US Patent 11219674 Therapeutic cancer vaccine
Patent 11219674 was granted and assigned to Cadila Pharmaceuticals on January, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 13 Dec, 2023
Golden AI
Edits made to:
Article (+447 characters)
Article
Patent abstract
The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method of preparing the same.
Edits on 15 Oct, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Avani Devenbhai Darji0
Bakulesh Mafatlal Khamar0
Chandreshwar Prasad Shukla0
Indravadan Ambalal Modi0
Nirav Manojkumar Desai0
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 13 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 11219674 Therapeutic cancer vaccine
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11219674
Date of patent
January 11, 2022
Patent application number
16404902
Date Filed
May 7, 2019
Patent primary examiner
Find more entities like US Patent 11219674 Therapeutic cancer vaccine
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.